Your browser is no longer supported. Please, upgrade your browser.
Settings
MIRM [NASD]
Mirum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.41 Insider Own0.40% Shs Outstand30.27M Perf Week10.09%
Market Cap624.37M Forward P/E- EPS next Y-3.00 Insider Trans-57.29% Shs Float27.84M Perf Month35.53%
Income-153.10M PEG- EPS next Q-1.61 Inst Own78.90% Short Float1.66% Perf Quarter12.11%
Sales11.00M P/S56.76 EPS this Y-79.10% Inst Trans0.41% Short Ratio4.66 Perf Half Y10.39%
Book/sh3.16 P/B6.39 EPS next Y39.80% ROA-71.80% Target Price- Perf Year9.67%
Cash/sh7.23 P/C2.79 EPS next 5Y- ROE-117.40% 52W Range13.85 - 26.31 Perf YTD15.58%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.30% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low45.70% ATR0.83
Employees120 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)79.67 Volatility4.96% 5.05%
OptionableYes Debt/Eq0.00 EPS Q/Q-55.90% Profit Margin- Rel Volume2.50 Prev Close19.46
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume99.07K Price20.18
Recom1.40 SMA2014.96% SMA5026.90% SMA20012.48% Volume247,851 Change3.70%
Sep-20-21Initiated JP Morgan Overweight $30
Aug-07-20Upgrade Raymond James Outperform → Strong Buy $28 → $48
Aug-03-20Initiated H.C. Wainwright Buy $52
Jul-31-20Initiated Piper Sandler Overweight $77
Jun-25-20Initiated Robert W. Baird Outperform $30
Aug-12-19Initiated ROTH Capital Buy $33
Aug-12-19Initiated Raymond James Outperform $28
Aug-12-19Initiated Guggenheim Buy $18
Aug-12-19Initiated Evercore ISI Outperform
Aug-12-19Initiated Citigroup Buy $21
Sep-22-21 08:55AM  
Sep-21-21 11:00AM  
08:00AM  
Sep-13-21 06:45AM  
Sep-10-21 05:30PM  
Sep-02-21 05:30PM  
Aug-26-21 08:53AM  
Aug-19-21 05:30PM  
Aug-10-21 07:00PM  
Aug-05-21 06:35PM  
04:02PM  
Jul-29-21 04:00PM  
Jul-27-21 06:59AM  
Jul-26-21 08:00PM  
Jul-12-21 06:00PM  
05:41AM  
Jun-24-21 04:05PM  
Jun-23-21 09:00AM  
Jun-16-21 09:00AM  
Jun-10-21 05:30PM  
Jun-07-21 09:00AM  
Jun-03-21 10:10AM  
May-26-21 09:00AM  
May-12-21 04:47AM  
May-10-21 09:00PM  
May-06-21 07:50PM  
04:05PM  
02:30PM  
Apr-29-21 04:05PM  
08:00AM  
Apr-26-21 09:00AM  
Apr-12-21 05:30PM  
08:00AM  
Mar-29-21 09:00AM  
Mar-13-21 03:39AM  
Mar-10-21 06:00PM  
Mar-09-21 05:25PM  
04:02PM  
09:09AM  
Feb-22-21 09:00AM  
Feb-10-21 05:30PM  
Feb-08-21 10:12AM  
Feb-01-21 09:00AM  
Jan-24-21 09:00AM  
Jan-14-21 09:00AM  
Jan-12-21 09:00AM  
Jan-08-21 06:17PM  
Jan-04-21 08:30AM  
Dec-30-20 02:45AM  
Dec-22-20 08:55AM  
Dec-14-20 09:00PM  
07:00AM  
Dec-10-20 10:33PM  
07:41PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Nov-30-20 08:30AM  
Nov-23-20 09:30AM  
Nov-15-20 06:00PM  
Nov-13-20 08:10AM  
Nov-12-20 09:00AM  
Nov-10-20 07:00PM  
Nov-05-20 08:30AM  
Nov-02-20 08:30AM  
Oct-26-20 08:30AM  
Oct-15-20 08:55AM  
08:45AM  
Oct-14-20 10:29AM  
Oct-13-20 04:05PM  
Sep-11-20 04:30PM  
07:00AM  
Sep-01-20 09:00AM  
Aug-29-20 08:45AM  
Aug-11-20 05:30PM  
09:42AM  
09:37AM  
Aug-07-20 04:05PM  
Aug-06-20 04:05PM  
Jul-10-20 05:00PM  
Jun-22-20 02:06PM  
Jun-11-20 04:10PM  
Jun-02-20 08:30AM  
May-29-20 10:05AM  
May-11-20 05:01PM  
May-07-20 04:05PM  
Apr-28-20 04:19PM  
Mar-12-20 04:02PM  
Feb-18-20 04:01PM  
Jan-16-20 09:00AM  
Jan-14-20 09:00AM  
Jan-08-20 08:15PM  
Dec-24-19 10:40AM  
Dec-17-19 07:56AM  
Dec-16-19 08:00AM  
Dec-13-19 04:28PM  
Nov-25-19 08:30AM  
08:30AM  
Nov-08-19 08:05AM  
Nov-06-19 04:05PM  
Oct-28-19 04:05PM  
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James E10% OwnerJul 09Sale15.8199,3251,570,3280Jul 13 12:06 PM
Flynn James E10% OwnerJul 07Sale15.876,837108,49699,325Jul 07 06:48 PM
Flynn James E10% OwnerJul 06Sale16.2049,239797,426106,162Jul 07 06:48 PM
Flynn James E10% OwnerJul 02Sale17.0110,599180,300155,401Jul 07 06:48 PM
Tucker Edwin JonathanChief Medical OfficerMar 05Option Exercise7.701,0828,33137,524Mar 08 06:40 PM
Tucker Edwin JonathanChief Medical OfficerDec 28Option Exercise7.704,16732,08636,442Dec 29 04:24 PM
Clements IanChief Financial OfficerDec 23Buy18.612,47045,9757,841Dec 28 04:12 PM
Peetz ChristopherPresident and CEODec 23Buy18.705,00093,480201,570Dec 28 04:06 PM
Tucker Edwin JonathanChief Medical OfficerOct 30Option Exercise7.7025,000192,50031,000Nov 03 05:09 PM